Q) Not true about use of Bevacizumab (Free Ans) (Onco AIIMS)
a) It is a humanized monoclonal antibody against VEGF A
b) Bevacizumab is a first-line treatment in metastatic nonsquamous non-small cell lung cancer.
c) Bevacizumab is a first-line or second-line therapy for metastatic colorectal cancer
d) Its major advantage is that it has replaced combination chemotherapy
Ans d) It is used in combination with other drugs
a) is true
Bevacizumab is a first-line treatment in combination with carboplatin and paclitaxel for recurrent, locally advanced, unresectable, or metastatic nonsquamous non-small cell lung cancer.
Bevacizumab is a first-line or second-line therapy for metastatic colorectal cancer when used in combination with fluorouracil (FU)-based chemotherapy regimens.
OTher FDA approved indications of Bevacizumab are
Cervical cancer, Metastatic RCC, Glioblastoma, Ovarian cancer
IT is always used with other drugs which are specific for the disease
AN important side effect is GI bleed and GI perforations
